全文获取类型
收费全文 | 277204篇 |
免费 | 41603篇 |
国内免费 | 6931篇 |
专业分类
耳鼻咽喉 | 6598篇 |
儿科学 | 7745篇 |
妇产科学 | 4153篇 |
基础医学 | 18994篇 |
口腔科学 | 3928篇 |
临床医学 | 40983篇 |
内科学 | 67257篇 |
皮肤病学 | 10518篇 |
神经病学 | 22137篇 |
特种医学 | 12058篇 |
外国民族医学 | 22篇 |
外科学 | 53568篇 |
综合类 | 14444篇 |
现状与发展 | 87篇 |
一般理论 | 21篇 |
预防医学 | 17173篇 |
眼科学 | 6383篇 |
药学 | 14130篇 |
80篇 | |
中国医学 | 5308篇 |
肿瘤学 | 20151篇 |
出版年
2024年 | 939篇 |
2023年 | 6009篇 |
2022年 | 4588篇 |
2021年 | 7932篇 |
2020年 | 9372篇 |
2019年 | 5445篇 |
2018年 | 10747篇 |
2017年 | 10580篇 |
2016年 | 11914篇 |
2015年 | 13732篇 |
2014年 | 21995篇 |
2013年 | 22894篇 |
2012年 | 16281篇 |
2011年 | 16326篇 |
2010年 | 17705篇 |
2009年 | 20373篇 |
2008年 | 13518篇 |
2007年 | 11449篇 |
2006年 | 13408篇 |
2005年 | 9887篇 |
2004年 | 7717篇 |
2003年 | 6106篇 |
2002年 | 5684篇 |
2001年 | 6218篇 |
2000年 | 5126篇 |
1999年 | 4885篇 |
1998年 | 4400篇 |
1997年 | 4217篇 |
1996年 | 3923篇 |
1995年 | 3772篇 |
1994年 | 2412篇 |
1993年 | 1954篇 |
1992年 | 2178篇 |
1991年 | 2212篇 |
1990年 | 1754篇 |
1989年 | 1874篇 |
1988年 | 1701篇 |
1987年 | 1502篇 |
1986年 | 1444篇 |
1985年 | 1266篇 |
1984年 | 981篇 |
1983年 | 883篇 |
1982年 | 770篇 |
1981年 | 650篇 |
1980年 | 582篇 |
1979年 | 644篇 |
1978年 | 629篇 |
1977年 | 605篇 |
1973年 | 471篇 |
1972年 | 499篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
Srdan Verstovsek MD PhD Jean-Jacques Kiladjian MD PhD Alessandro M. Vannucchi MD Ruben A. Mesa MD FACP Peg Squier MD PhD J. E. Hamer-Maansson MSPH Claire Harrison MD 《Cancer》2023,129(11):1681-1690
Background
In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT-I) and COMFORT-II clinical trials, adult patients with intermediate-2 or high-risk myelofibrosis who received oral ruxolitinib at randomization or after crossover from placebo or best available therapy (BAT) had improved overall survival (OS).Methods
This post hoc analysis of pooled COMFORT data examined relevant disease outcomes based on the disease duration (≤12 or >12 months from diagnosis) before ruxolitinib initiation.Results
The analysis included 525 patients (ruxolitinib: ≤12 months, n = 84; >12 months, n = 216; placebo/BAT: ≤12 months, n = 66; >12 months, n = 159); the median age was 65.0–70.0 years. Fewer thrombocytopenia and anemia events were observed among patients who initiated ruxolitinib treatment earlier. At Weeks 24 and 48, the spleen volume response (SVR) was higher for patients who initiated ruxolitinib earlier (47.6% vs. 32.9% at Week 24, p = .0610; 44.0% vs. 26.9% at Week 48, p = .0149). In a multivariable analysis of factors associated with spleen volume reduction, a logistic regression model that controlled for confounding factors found that a significantly greater binary reduction was observed among patients with shorter versus longer disease duration (p = .022). At Week 240, OS was significantly improved among patients who initiated ruxolitinib earlier (63% [95% CI, 51%‒73%] vs. 57% [95% CI, 49%‒64%]; hazard ratio, 1.53; 95% CI, 1.01‒2.31; p = .0430). Regardless of disease duration, a longer OS was observed for patients who received ruxolitinib versus those who received placebo/BAT.Conclusions
These findings suggest that earlier ruxolitinib initiation for adult patients with intermediate-2 and high-risk myelofibrosis may improve clinical outcomes, including fewer cytopenia events, durable SVR, and prolonged OS.Plain Language Summary
- Patients with myelofibrosis, a bone marrow cancer, often do not live as long as the general population. These patients may also have an enlarged spleen and difficult symptoms such as fatigue.
- Two large clinical trials showed that patients treated with the drug ruxolitinib lived longer and had improved symptoms compared to those treated with placebo or other standard treatments.
- Here it was examined whether starting treatment with ruxolitinib earlier (i.e., within a year of diagnosis) provided benefits versus delaying treatment.
- Patients who received ruxolitinib within a year of diagnosis lived longer and experienced fewer disease symptoms than those whose treatment was delayed.
4.
Elizabeth A. Mosley PhD MPH Amy J. Schulz PhD MPH MSW Lisa H. Harris MD PhD Barbara A. Anderson PhD 《Women & health》2020,60(7):806-820
ABSTRACT Abortion is legal in South Africa, but negative abortion attitudes remain common and are poorly understood. We used nationally representative South African Social Attitudes Survey data to analyze abortion attitudes in the case of fetal anomaly and in the case of poverty from 2007 to 2016 (n = 20,711; ages = 16+). We measured correlations between abortion attitudes and these important predictors: religiosity, attitudes about premarital sex, attitudes about preferential hiring and promotion of women, and attitudes toward family gender roles. Abortion acceptability for poverty increased over time (b = 0.05, p < .001), but not for fetal anomaly (b = ?0.008, p = .284). Highly religious South Africans reported lower abortion acceptability in both cases (Odds Ratio (OR)anomaly = 0.85, p = .015; ORpoverty = 0.84, p = .02). Premarital sex acceptability strongly and positively predicted abortion acceptability (ORanomaly = 2.63, p < .001; ORpoverty = 2.46, p < .001). Attitudes about preferential hiring and promotion of women were not associated with abortion attitudes, but favorable attitudes about working mothers were positively associated with abortion acceptability for fetal anomaly ((ORanomaly = 1.09, p = .01; ORpoverty = 1.02, p = .641)). Results suggest negative abortion attitudes remain common in South Africa and are closely tied to religiosity, traditional ideologies about sexuality, and gender role expectations about motherhood. 相似文献
5.
6.
目的:探究超脉冲CO2点阵激光联合富血小板血浆(PRP)治疗面部痤疮凹陷性瘢痕的疗效。方法:72例面部痤疮凹陷性瘢痕患者,随机分为观察组(36例)和对照组(36例)。对照组采用超脉冲CO2点阵激光治疗,观察组采用超脉冲CO2点阵激光联合PRP治疗。比较两组患者的灰度差异、时间指标、瘢痕程度、疼痛、不良反应及视觉评估。结果:观察组的并发症发生率为11.11%,低于对照组的36.11%,差异具有统计学意义(P<0.05)。治疗后,两组患者的灰度差异率均减小,且观察组患者的灰度差异率显著低于对照组,差异具有统计学意义(P<0.05)。治疗后,观察组的炎性渗出时间、红肿时间、愈合时间、停工时间及瘢痕程度评分均低于对照组,差异均具有统计学意义(P<0.05);但疼痛度评分组间比较,差异无统计学意义(P>0.05)。结论:超脉冲CO2点阵激光联合PRP治疗面部痤疮凹陷性瘢痕效果较好,可有效降低瘢痕程度,减少治疗时间及并发症的发生,帮助患者迅速回归正常工作与生活,值得临床推广使用。 相似文献
7.
目的:探究金水宝片联合依诺肝素对维持性血液透析患者血脂代谢的影响。方法:选取2018年12月至2019年3月马鞍山十七冶医院血液净化中心进行透析的患者154例作为研究对象,根据用药不同分为对照组和观察组,每组77例。对照组常规应用依诺肝素抗凝,观察组在对照组抗凝基础上加用金水宝片,各组均干预3个月,比较2组患者血脂变化及持续血液透析并发症发生情况。结果:治疗后,观察组患者三酰甘油、总胆固醇及低密度脂蛋白胆固醇水平下降,高密度脂蛋白胆固醇升高,与治疗前比较差异均有统计学意义(P<0.05),与对照组治疗后比较,差异有统计学意义(P<0.05);观察组总并发症发生率明显低于对照组,2组比较差异有统计学意义(P<0.05);2组患者维持性血液透析不良反应发生率均较低,组间比较差异无统计学意义(P>0.05)。结论:金水宝片联合依诺肝素有助于改善维持性血液透析患者血脂代谢水平,降低维持性血液透析相关并发症,值得临床推广应用。 相似文献
8.
9.
10.